•
Dec 31, 2021

Molina Q4 2021 Earnings Report

Molina Healthcare reported strong Q4 and year-end results, driven by membership growth and disciplined cost management.

Key Takeaways

Molina Healthcare reported GAAP earnings per diluted share of $1.74 and adjusted earnings per diluted share of $2.88 for the fourth quarter of 2021. The company served approximately 5.2 million members as of December 31, 2021, an increase of 1.2 million members or 29% year over year.

Molina Healthcare served approximately 5.2 million members as of December 31, 2021, a 29% increase year over year.

Premium revenue was approximately $26.9 billion for the full year 2021, a 47% increase year over year.

The company issued its full year 2022 earnings guidance with premium revenue of approximately $28.5 billion and 26% adjusted EPS growth to no less than $17.00 per diluted share.

On January 3, 2022, the Company announced that it closed its acquisition of Cigna Corporation’s Texas Medicaid contracts on January 1, 2022.

Total Revenue
$7.41B
Previous year: $5.24B
+41.5%
EPS
$2.88
Previous year: -$0.51
-664.7%
Medicaid Membership
4.33M
Previous year: 3.6M
+20.3%
Medicare Membership
142K
Previous year: 115K
+23.5%
Marketplace Membership
728K
Previous year: 318K
+128.9%
Gross Profit
$836M
Previous year: $587M
+42.4%
Cash and Equivalents
$4.44B
Previous year: $4.15B
+6.8%
Free Cash Flow
$576M
Previous year: $1.29B
-55.3%
Total Assets
$12.2B
Previous year: $9.53B
+28.1%

Molina

Molina

Molina Revenue by Segment

Forward Guidance

The Company expects its full year 2022 total revenue to be approximately $29.5 billion. Premium revenue for the full year 2022 is expected to be approximately $28.5 billion. The Company expects its full year 2022 adjusted earnings per share to be no less than $17.00 per share.

Positive Outlook

  • Lower net effect of COVID
  • Continued strong performance in Medicare and Medicaid
  • The restoration of mid-single digit pretax margin in our Marketplace business
  • Full Year 2022 total revenue to be approximately $29.5 billion
  • Full year 2022 adjusted earnings per share to be no less than $17.00 per share

Challenges Ahead

  • The impact of regulatory headwinds created by the mid-year resumption of redeterminations
  • The carveout of pharmacy benefits in our California and Ohio contracts

Revenue & Expenses

Visualization of income flow from segment revenue to net income